Pasithea Therapeutics Updates Time of Presentation at the H.C. Wainwright 27th Annual Global Investment Conference

Core Points - Pasithea Therapeutics Corp. is a clinical-stage biotechnology company focused on developing PAS-004, a next-generation macrocyclic MEK inhibitor for treating RASopathies and MAPK pathway-driven tumors [2] - The company will present at the H.C. Wainwright 27 Annual Global Investment Conference on September 8, 2025, at 5:00 PM ET [1][2] - PAS-004 is currently undergoing a Phase 1 clinical trial for advanced cancer patients and a Phase 1/1b clinical trial for adult patients with neurofibromatosis type 1-associated plexiform neurofibromas [2] Event Details - The presentation will take place at the Lotte New York Palace Hotel during the H.C. Wainwright 27 Annual Global Investment Conference [2] - Management will be available for one-on-one meetings throughout the event [2]